Cell therapy startups Arsenal Biosciences and X4 Pharmaceuticals announced significant layoffs, cutting their workforces by half amid ongoing restructuring. Arsenal Bio pivoted towards clinical-stage operations following a $325 million Series C raise, while X4 Pharmaceuticals also reduced staff including executives. These moves reflect broader funding and market challenges confronted by biotech firms, emphasizing strategic refocusing and cost containment in a fluctuating investment environment.